Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41598-017-11126-y http://scihub22266oqcxt.onion/10.1038/s41598-017-11126-y C5587706!5587706 !28878363     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=28878363 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28878363 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Sci+Rep 2017 ; 7 (1 ): 10713 Nephropedia Template TP {{tp|p=28878363 |t=2017. A TCR-based Chimeric Antigen Receptor |pdf=|usr=}}{{28878363 }} gab.com Text A TCR-based Chimeric Antigen Receptor JO: Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=28878363 #FOAvip Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection. Although very potent, CAR recognition is limited to membrane antigens which represent around 1% of the total proteins expressed, whereas TCRs have the advantage of targeting any peptide resulting from cellular protein degradation. However, TCRs depend on heavy signalling machinery only present in T cells which restricts the type of eligible therapeutic cells. Hence, an introduced therapeutic TCR will compete with the endogenous TCR for the signalling proteins and carries the potential risk of mixed dimer formation giving rise to a new TCR with unpredictable specificity. We have fused a soluble TCR construct to a CAR-signalling tail and named the final product TCR-CAR. We here show that, if expressed, the TCR-CAR conserved the specificity and the functionality of the original TCR. In addition, we demonstrate that TCR-CAR redirection was not restricted to T cells. Indeed, after transduction, the NK cell line NK-92 became TCR positive and reacted against pMHC target. This opens therapeutic avenues combing the killing efficiency of NK cells with the diversified target recognition of TCRs. Twit Text FOAVip A TCR-based Chimeric Antigen Receptor ????Sci Rep http://www.kidney.de/pget.php?&tw=1&pmid=28878363 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28878363 #FOAvip English Wikipedia <ref>{{Cite pmid|28878363 }}</ref> A TCR-based Chimeric Antigen Receptor #MMPMID28878363 Walseng E ; Köksal H ; Sektioglu IM ; Fåne A ; Skorstad G ; Kvalheim G ; Gaudernack G ; Inderberg EM ; Wälchli S Sci Rep 2017[Sep]; 7 (1 ): 10713 PMID28878363 show ga Effector T cells equipped with engineered antigen receptors specific for cancer targets have proven to be very efficient. Two methods have emerged: the Chimeric Antigen Receptors (CARs) and T-cell Receptor (TCR) redirection. Although very potent, CAR recognition is limited to membrane antigens which represent around 1% of the total proteins expressed, whereas TCRs have the advantage of targeting any peptide resulting from cellular protein degradation. However, TCRs depend on heavy signalling machinery only present in T cells which restricts the type of eligible therapeutic cells. Hence, an introduced therapeutic TCR will compete with the endogenous TCR for the signalling proteins and carries the potential risk of mixed dimer formation giving rise to a new TCR with unpredictable specificity. We have fused a soluble TCR construct to a CAR-signalling tail and named the final product TCR-CAR. We here show that, if expressed, the TCR-CAR conserved the specificity and the functionality of the original TCR. In addition, we demonstrate that TCR-CAR redirection was not restricted to T cells. Indeed, after transduction, the NK cell line NK-92 became TCR positive and reacted against pMHC target. This opens therapeutic avenues combing the killing efficiency of NK cells with the diversified target recognition of TCRs. |Cell Line, Tumor [MESH] |Cytokines/metabolism [MESH] |Cytotoxicity, Immunologic [MESH] |Flow Cytometry [MESH] |Gene Expression [MESH] |Gene Order [MESH] |Genetic Vectors/genetics [MESH] |Histocompatibility Antigens Class I/immunology/metabolism [MESH] |Humans [MESH] |Immunotherapy, Adoptive [MESH] |Killer Cells, Natural/immunology/metabolism [MESH] |Protein Interaction Domains and Motifs/genetics [MESH] |Receptors, Antigen, T-Cell/chemistry/*genetics/*metabolism [MESH] |Receptors, Chimeric Antigen/chemistry/*genetics/*metabolism [MESH] |Recombinant Fusion Proteins [MESH] |T-Lymphocytes/immunology/metabolism [MESH]A TCR-based Chimeric Antigen Receptor (epmc).pdf DeepDyve Pubget Overpricing